Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 20855825

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2010 Oct 20
First author
Di Leo A

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2011 Jun 1;29(16):2293
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    J Clin Oncol. 2010 Oct 20;28(30):4548-50. doi: 10.1200/JCO.2010.30.6266.
    note
    Source null
    related pmid
    20855842
    relationship
    Comment in
  3. citation
    Clin Breast Cancer. 2011 Aug;11(4):195. doi: 10.1016/j.clbc.2011.02.005.
    note
    Source null
    related pmid
    21729663
    relationship
    Comment in

Authors and identifiers

  1. name
    Di Leo A
    type
    Author
  2. name
    Jerusalem G
    type
    Author
  3. name
    Petruzelka L
    type
    Author
  4. name
    Torres R
    type
    Author
  5. name
    Bondarenko IN
    type
    Author
  6. name
    Khasanov R
    type
    Author
  7. name
    Verhoeven D
    type
    Author
  8. name
    Pedrini JL
    type
    Author
  9. name
    Smirnova I
    type
    Author
  10. name
    Lichinitser MR
    type
    Author
  11. name
    Pendergrass K
    type
    Author
  12. name
    Garnett S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Di Leo A
    type
    Author
  2. name
    Jerusalem G
    type
    Author
  3. name
    Petruzelka L
    type
    Author
  4. name
    Torres R
    type
    Author
  5. name
    Bondarenko IN
    type
    Author
  6. name
    Khasanov R
    type
    Author
  7. name
    Verhoeven D
    type
    Author
  8. name
    Pedrini JL
    type
    Author
  9. name
    Smirnova I
    type
    Author
  10. name
    Lichinitser MR
    type
    Author
  11. name
    Pendergrass K
    type
    Author
  12. name
    Garnett S
    type
    Author
bibliography ids
  1. nci-bib-3f36f58f8c54d296d4ede406
book metadata
content sha256
6636b257923c24a6c5ab283ad28c1b7fc192e29cf436311733d37116fa9cfdf7
document type
citation
dois
  1. 10.1200/JCO.2010.28.8415
electronic publication date
display
2010 Sep 20
precision
day
year
2010
evidence scope
bibliographic_metadata_only
id
pubmed:20855825
immutable id
pubmed:20855825@6636b257923c24a6c5ab283ad28c1b7fc192e29cf436311733d37116fa9cfdf7
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
30
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
4594-600
volume
28
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2011 Jun 1;29(16):2293
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    J Clin Oncol. 2010 Oct 20;28(30):4548-50. doi: 10.1200/JCO.2010.30.6266.
    note
    Source null
    related pmid
    20855842
    relationship
    Comment in
  3. citation
    Clin Breast Cancer. 2011 Aug;11(4):195. doi: 10.1016/j.clbc.2011.02.005.
    note
    Source null
    related pmid
    21729663
    relationship
    Comment in
outcomes validated
false
pmid
20855825
provenance
batch id
10a38257e12e9ed1867a
provider
NCBI PubMed ESummary
record sha256
36d707c532474eed0066f0bb309a9801766056f3ffdfbc53be1c029f81d994bd
response sha256
84c4808ca38b35d999cfdf809eb088835175ab38d71586c626096d677096bbcc
retrieved at
2026-09-09T23:46:35.793530+00:00
publication date
display
2010 Oct 20
precision
day
year
2010
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/20855825/
title
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Preserved source evidence · Not medical advice